Anebulo’s CEO, Simon Allen will be joined by Founder Dr. Joseph Lawler, CSO Dr. Ken Cundy and other senior executives to discuss the company’s eyesight, progress update on Anebulo’s ongoing Section 2 evidence-of-strategy study associated to ANEB-001, commercialization/partnership approach, and target fiscal product. The occasion will consist of a issue-and-answer session following displays by Administration.
Institutional traders and financial analysts are invited to show up at and can register through e mail at [email protected]. For additional details, be sure to call Samantha Alphonso at [email protected] or (212) 827-3746 as area is limited.
About Anebulo Prescription drugs, Inc.
Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical enterprise developing novel solutions for folks suffering from acute cannabinoid intoxication and substance abuse ailment. Its guide products prospect, ANEB-001, is now in a Stage 2 clinical trial (www.clinicaltrials.gov/ct2/exhibit/NCT05282797) to examine its utility in reversing the adverse results of acute cannabinoid intoxication in just one hour of administration. This demo is getting run in the Netherlands by the Centre for Human Drug Research (CHDR). ANEB-001 is a aggressive antagonist at the human cannabinoid receptor variety 1 (CB1). For more information and facts about Anebulo, make sure you go to www.anebulo.com.
Forward-Searching Statements
This push launch contains ahead-hunting statements as outlined in Section 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Exchange Act of 1934, as amended. These forward-searching statements, along with terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” and other equivalent conditions, contain challenges and uncertainties mainly because they relate to situations and depend on instances that will occur in the future. All those statements involve statements concerning the intent, perception or present-day expectations of Anebulo and associates of its management, as perfectly as the assumptions on which this sort of statements are based. Possible investors are cautioned that any such ahead-seeking statements are not guarantees of potential overall performance and include threats and uncertainties, like hazards attendant to acquiring, tests and commercializing the company’s product candidates, and those people explained in Anebulo’s most modern once-a-year report on Type 10-K and in other periodic stories filed with the SEC, and that real success could vary materially from people contemplated by these kinds of ahead-hunting statements. Apart from as required by federal securities law, Anebulo undertakes no obligation to update or revise ahead-looking statements to mirror transformed conditions.
Contacts
Anebulo Prescribed drugs, Inc.
Scott Anderson
Head of Investor Relations and General public Relations
(858) 229-7063
[email protected]
Rex Service provider
Chief Monetary Officer
(512) 598-0931
[email protected]
